Rapid de-localization of actin leading edge components with BDM treatment

<p>Abstract</p> <p>Background</p> <p>2,3-Butanedione monoxime (BDM) has been widely used as a non-muscle myosin inhibitor to investigate the role of non-muscle myosinII in the process of actin retrograde flow and other actin cytoskeletal processes. Recent reports show t...

Full description

Bibliographic Details
Main Authors: Lechler Terry, Yarrow Justin C, Li Rong, Mitchison Timothy J
Format: Article
Language:English
Published: BMC 2003-06-01
Series:BMC Cell Biology
Online Access:http://www.biomedcentral.com/1471-2121/4/5
_version_ 1818234515288489984
author Lechler Terry
Yarrow Justin C
Li Rong
Mitchison Timothy J
author_facet Lechler Terry
Yarrow Justin C
Li Rong
Mitchison Timothy J
author_sort Lechler Terry
collection DOAJ
description <p>Abstract</p> <p>Background</p> <p>2,3-Butanedione monoxime (BDM) has been widely used as a non-muscle myosin inhibitor to investigate the role of non-muscle myosinII in the process of actin retrograde flow and other actin cytoskeletal processes. Recent reports show that BDM does not inhibit any non-muscle myosins so far tested, including nm-myosinII, prompting the question, how were these process affected in BDM studies?</p> <p>Results</p> <p>We have found that treatment of mammalian cells with BDM for only 1 min blocks actin incorporation at the leading edge in a permeabilized cell system. We show that inhibition of actin incorporation occurs through de-localization of leading edge proteins involved in actin polymerization – the Arp2/3 complex, WAVE, and VASP – that de-localize concomitantly with the leading edge actin network.</p> <p>Conclusion</p> <p>De-localization of actin leading edge components by BDM treatment is a newly described effect of this compound. It may explain many of the results previously ascribed to inhibition of non-muscle myosinII by BDM, particularly in studies of leading edge dynamics. Though this effect of BDM is intriguing, future studies probing actin dynamics at the leading edge should use more potent and specific inhibitors.</p>
first_indexed 2024-12-12T11:39:18Z
format Article
id doaj.art-9498b901074b44ee8845e23d66cab86e
institution Directory Open Access Journal
issn 1471-2121
language English
last_indexed 2024-12-12T11:39:18Z
publishDate 2003-06-01
publisher BMC
record_format Article
series BMC Cell Biology
spelling doaj.art-9498b901074b44ee8845e23d66cab86e2022-12-22T00:25:35ZengBMCBMC Cell Biology1471-21212003-06-0141510.1186/1471-2121-4-5Rapid de-localization of actin leading edge components with BDM treatmentLechler TerryYarrow Justin CLi RongMitchison Timothy J<p>Abstract</p> <p>Background</p> <p>2,3-Butanedione monoxime (BDM) has been widely used as a non-muscle myosin inhibitor to investigate the role of non-muscle myosinII in the process of actin retrograde flow and other actin cytoskeletal processes. Recent reports show that BDM does not inhibit any non-muscle myosins so far tested, including nm-myosinII, prompting the question, how were these process affected in BDM studies?</p> <p>Results</p> <p>We have found that treatment of mammalian cells with BDM for only 1 min blocks actin incorporation at the leading edge in a permeabilized cell system. We show that inhibition of actin incorporation occurs through de-localization of leading edge proteins involved in actin polymerization – the Arp2/3 complex, WAVE, and VASP – that de-localize concomitantly with the leading edge actin network.</p> <p>Conclusion</p> <p>De-localization of actin leading edge components by BDM treatment is a newly described effect of this compound. It may explain many of the results previously ascribed to inhibition of non-muscle myosinII by BDM, particularly in studies of leading edge dynamics. Though this effect of BDM is intriguing, future studies probing actin dynamics at the leading edge should use more potent and specific inhibitors.</p>http://www.biomedcentral.com/1471-2121/4/5
spellingShingle Lechler Terry
Yarrow Justin C
Li Rong
Mitchison Timothy J
Rapid de-localization of actin leading edge components with BDM treatment
BMC Cell Biology
title Rapid de-localization of actin leading edge components with BDM treatment
title_full Rapid de-localization of actin leading edge components with BDM treatment
title_fullStr Rapid de-localization of actin leading edge components with BDM treatment
title_full_unstemmed Rapid de-localization of actin leading edge components with BDM treatment
title_short Rapid de-localization of actin leading edge components with BDM treatment
title_sort rapid de localization of actin leading edge components with bdm treatment
url http://www.biomedcentral.com/1471-2121/4/5
work_keys_str_mv AT lechlerterry rapiddelocalizationofactinleadingedgecomponentswithbdmtreatment
AT yarrowjustinc rapiddelocalizationofactinleadingedgecomponentswithbdmtreatment
AT lirong rapiddelocalizationofactinleadingedgecomponentswithbdmtreatment
AT mitchisontimothyj rapiddelocalizationofactinleadingedgecomponentswithbdmtreatment